Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the venous thromboembolism market grown over the years?

The venous thromboembolism market has experienced steady growth, set to increase from $2.44 billion in 2024 to $2.55 billion in 2025, with a 4.4% CAGR. Factors contributing to this growth include an aging population, advancements in anticoagulant therapies, reimbursement policies, and increased investment in the sector.

What Is the forecasted market size and growth rate for the venous thromboembolism market?

The venous thromboembolism market is expected to witness steady growth, reaching $3.02 billion in 2029 at a CAGR of 4.4%. Growth will be supported by improved global healthcare access, the adoption of genetic risk assessments, increased use of telemedicine, and enhanced patient education programs. Emerging trends include extended thromboprophylaxis, the adoption of novel oral anticoagulants, personalized treatment plans, and advancements in diagnostic imaging.

Get your venous thromboembolism market report here!

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

What are the major factors driving growth in the venous thromboembolism market?

The venous thromboembolism market is expected to flourish with the growth of the healthcare infrastructure. Products and services aimed at treating, curing, preventing, and providing necessary care for patients fall under the healthcare industry. The industry’s growth aids the improvement of necessary policies, educational programs, and institutional frameworks needed to implement VTE prevention protocols. As reported by the American Health Care Association in May 2023, there was an increase in the number of hospitals in the US to 6,129 from 6,093 in the previous year. Also, in the same month, the Office for National Statistics reported that the UK’s healthcare expenditure was around £292 billion in 2023, indicating a nominal rise of 5.6%. The long-term health and social care expenditure also saw a real-terms increase of 2.8%. These statistics establish that the growth of the healthcare industry significantly contributes to the venous thromboembolism market’s expansion. Additionally, another significant factor propelling the growth of the venous thromboembolism market is the rise in orthopedic procedures. These procedures play a pivotal role in treating spine and joint-related disorders and correcting skeletal abnormalities. Procedures like total knee arthroplasty (TKA), total hip arthroplasty (THA), or hip fracture surgery (HFS), known for their heightened risk of VTE, have led to an increased reliance on compression devices to prevent DVT. These devices are crucial in stoping the formation of blood clots in one’s deep leg veins, a major cause of venous thromboembolism (VTE). The National Library of Medicine reported in February 2023 that the number of THA and TKA procedures are expected to surge to 719,364 and 1,222,988, respectively, by 2040. Furthermore, by 2060, it is anticipated that TKAs and THAs will amount to 2,917,959 and 1,982,099 respectively. This surge in orthopedic procedures thus significantly propels the venous thromboembolism market’s growth.

What key areas define the segmentation of the global venous thromboembolism Market?

The venous thromboembolism market covered in this report is segmented –

1) By Type: Deep Vein Thrombosis, Pulmonary Embolism, Other Types

2) By Treatment: Anti-Clotting Medications,  Mechanical Devices, Thrombolytic Therapy, Other Treatment

3) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By Deep Vein Thrombosis (DVT): Proximal DVT, Distal DVT, Asymptomatic DVT

2) By Pulmonary Embolism (PE): Acute PE, Chronic PE, Submassive PE

3) By Other Types: Thrombophlebitis, Superficial Vein Thrombosis, Post-Thrombotic Syndrome

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

What are the top market players propelling the growth of the venous thromboembolism industry?

Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

What are the key trends shaping the future of the venous thromboembolism market?

In a bid to bolster their standing in the venous thromboembolism market, major companies are innovating new anticoagulant medications and therapies. Such progress in anticoagulation can potentially yield more effective treatments for preventing or mitigating venous thromboembolism. Illustratively, Anthos Therapeutics, an American company that specializes in clinical-stage biotherapeutic products, secured regulatory clearance from the U.S Food and Drug Administration for their abelacimab anticoagulant drug in September 2022. This new drug, a fully human monoclonal antibody, was approved for reducing the risk of stroke and systemic embolism in individuals with atrial fibrillation. The recent innovation of the dual-action antibody abelacimab, administered monthly, is designed to enable hemostasis-sparing anticoagulation through the inhibition of Factor XI.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13001

What regions are dominating the venous thromboembolism market growth?

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Blood And Blood Components Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Patient Blood Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: